跳至主要内容
临床试验/NCT07147569
NCT07147569招募中不适用

GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Marketing Surveillance

W.L.Gore & Associates5 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2026年3月27日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
100
试验地点
5
主要终点
Technical Success

研究概览

简要总结

To evaluate the safety and efficacy of multi component system (TAMBE device) including GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (Aortic Component; AC) under post-marketing use.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients who were attempted to implant the AC
  • Thoracoabdominal aortic aneurysm
  • Pararenal abdominal aortic aneurysm

排除标准

  • 未提供

研究组 & 干预措施

TAMBE

干预措施: GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (Device)

结局指标

主要结局

Technical Success

时间窗: From the initial incision or puncture of the access vessel for the implantation procedure to the closure of the access vessel

Calculate the rate of achievement of technical success at the index procedure. The technical success is defined as follows. \[Technical success\] All of the following qualifying criteria are met: * Successful access to the access vessels * Successful delivery and deployment of AC and all stent grafts used in combination with AC to its intended location * Successful side branch delivery catheterization and placement of all stent grafts used in the side branch area to its intended location * Absence of type I or type III endoleaks at final completion image evaluation * Patency of AC and all stent grafts used in combination with AC at final completion image evaluation * Absence of open surgical repair conversion or mortality

Clinical Success

时间窗: 12 Months

The achievement rate of clinical success will be calculated. The clinical success is defined as follows. \[Clinical Success\] * Achievement of technical success * Absence of the events listed below from the time of the index procedure to 12 months after the index procedure 1. Death from the index procedure 2. Death from reintervention 3. Death from aorta-related causes 4. Persistent type I or type III endoleaks 5. Lesion enlargement \>5 mm 6. Device migration \>10 mm 7. Failure due to device integrity issues 8. Lesion rupture 9. Conversion to open surgical repair 10. Permanent paraplegia 11. Disabling stroke 12. New-onset dialysis

Results related to abdominal branch vessels

时间窗: 60 Months

Calculate the incidence of the following events related to abdominal branch vessels (celiac artery, superior mesenteric artery, left/ right renal arteries) or AC and stent grafts used in combination with AC for visceral branch vessels. * Primary Patency * Primary Assisted Patency * Secondary Patency * Occlusion * Stenosis * Kink * Target vessel instability * Intraprocedural Complications

Major Adverse Events (MAEs)

时间窗: 60 Months

The incidence of any of following events is calculated. * All-cause mortality * Myocardial infarction resulting in death, cardiac arrest, or cardiopulmonary resuscitation * Respiratory failure requiring prolonged (\> 24 hours) mechanical ventilation or reintubation * Renal function decline characterized by one or more of the following: 1. \> 50% reduction in pre-treatment Estimated Glomerular Filtration Rate (eGFR) 2. New-onset dialysis * Bowel ischemia requiring surgical resection or not resolving with medical therapy * Permanent paraplegia * Major stroke (Any fatal or disabling stroke).

Thirty-Day Mortality

时间窗: 30 Days

Calculate thirty-day mortality. Thirty-day mortality is defined as follows. \[Thirty-Day Mortality\] Any death that occurs at the index procedure, within the index procedure hospital stay, or within the first 30 days post-index procedure.

Lesion-Related Mortality

时间窗: 30 Days

Calculate lesion-related mortality. Lesion-related mortality is defined as follows. \[Lesion-related mortality\] Any death that occurs within the first 30 days, any death that results from lesion rupture, aorta-related adverse events (e.g., infection, occlusion, dissection, hematoma), or adverse events related to a secondary intervention.

Technical Success

时间窗: From the initial incision or puncture of the access vessel for the implantation procedure to the closure of the access vessel

Calculate the rate of achievement of technical success at the index procedure. The technical success is defined as follows. \[Technical success\] All of the following qualifying criteria are met: * Successful access to the access vessels * Successful delivery and deployment of AC and all stent grafts used in combination with AC to its intended location * Successful side branch delivery catheterization and placement of all stent grafts used in the side branch area to its intended location * Absence of type I or type III endoleaks at final completion image evaluation * Patency of AC and all stent grafts used in combination with AC at final completion image evaluation * Absence of open surgical repair conversion or mortality

Clinical Success

时间窗: 12 Months

The achievement rate of clinical success will be calculated. The clinical success is defined as follows. \[Clinical Success\] * Achievement of technical success * Absence of the events listed below from the time of the index procedure to 12 months after the index procedure 1. Death from the index procedure 2. Death from reintervention 3. Death from aorta-related causes 4. Persistent type I or type III endoleaks 5. Lesion enlargement \>5 mm 6. Device migration \>10 mm 7. Failure due to device integrity issues 8. Lesion rupture 9. Conversion to open surgical repair 10. Permanent paraplegia 11. Disabling stroke 12. New-onset dialysis

Results related to abdominal branch vessels

时间窗: 60 Months

Calculate the incidence of the following events related to abdominal branch vessels (celiac artery, superior mesenteric artery, left/ right renal arteries) or AC and stent grafts used in combination with AC for visceral branch vessels. * Primary Patency * Primary Assisted Patency * Secondary Patency * Occlusion * Stenosis * Kink * Target vessel instability * Intraprocedural Complications

Major Adverse Events (MAEs)

时间窗: 60 Months

The incidence of any of following events is calculated. * All-cause mortality * Myocardial infarction resulting in death, cardiac arrest, or cardiopulmonary resuscitation * Respiratory failure requiring prolonged (\> 24 hours) mechanical ventilation or reintubation * Renal function decline characterized by one or more of the following: 1. \> 50% reduction in pre-treatment Estimated Glomerular Filtration Rate (eGFR) 2. New-onset dialysis * Bowel ischemia requiring surgical resection or not resolving with medical therapy * Permanent paraplegia * Major stroke (Any fatal or disabling stroke).

Thirty-Day Mortality

时间窗: 30 Days

Calculate thirty-day mortality. Thirty-day mortality is defined as follows. \[Thirty-Day Mortality\] Any death that occurs at the index procedure, within the index procedure hospital stay, or within the first 30 days post-index procedure.

Lesion-Related Mortality

时间窗: 30 Days

Calculate lesion-related mortality. Lesion-related mortality is defined as follows. \[Lesion-related mortality\] Any death that occurs within the first 30 days, any death that results from lesion rupture, aorta-related adverse events (e.g., infection, occlusion, dissection, hematoma), or adverse events related to a secondary intervention.

Reintervention

时间窗: 60 Months

Calculate the incidence of reintervention. Reintervention will be classified as "major" or "minor". Reintervention and its classifications are defined as follows. \[Reintervention\] Any procedure after the index procedure on the AC and stent grafts used in combination with AC. \[Major Reintervention\] Deployment the stent graft for proximal or distal side, removal of AC and stent grafts used in combination with AC, use of thrombectomy or thrombolysis, and surgical procedure. \[Minor Reintervention\] Treatment other than major reintervention that falls under any of the following categories * Endovascular procedures (percutaneous transluminal angioplasty, atherectomy, stenting) * Interventions to treat branch vessel stenosis * Interventions to treat type II endoleaks or branch-related endoleaks.

次要结局

未报告次要终点

研究者

发起方
W.L.Gore & Associates
申办方类型
Industry
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验